|drug817||Colgate periogard mouthwash Wiki||1.00|
|drug815||Colgate Peroxyl mouthwash Wiki||1.00|
|drug2544||Placebo mouthwash (water) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The aim of this study is to analyze oral disinfection with 1.5% hydrogen peroxide, 0.12% chlorhexidine gluconate or 0.075% cetylpyridinium chloride to 0.28% zinc lactate to reduce the SARS-CoV viral load -2 in the oral and oropharyngeal mucosa and saliva. Patients of both sexes, aged between 18 and 90 years, positive for SARS-CoV-2 by the RT-PCR method and who require oral hygiene care and other preventive and therapeutic dental procedures that are used in the randomized clinical study. The study comprises two arms: Arm 1 - patients hospitalized in the ICU bed with orotracheal intubation - undergo disinfection of the oral mucosa with 1.5% hydrogen peroxide solution, after the 0.12% non-alcoholic chlorhexidine solution ( Peroxide and Chlorhexidine Group) or only disinfection of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution (Chlorhexidine Group - control); Arm 2 - patients hospitalized in the common bed without mechanical ventilation - will undergo oral disinfection or with 1.5% hydrogen peroxide solution (Peroxide Group), or with 0.12% chlorhexidine gluconate (Chlorhexidine Group) or with chloride 0.075% cetylpyridinium with 0.28% zinc lactate (Cetylpyridinium Group) or distilled water (Placebo Group). For the monitoring of viral load, the following procedures are performed: Arm 1 - a scrape with swab on the tongue, deep groove, oral soil, performed before the first oral disinfection (T0), after disinfection with hydrogen peroxide (T1) , after disinfection with chlorhexidine (T2) and 30 minutes after the last disinfection (T3); swab of the fluid adhered to the tube, before disinfecting the tube with hydrogen peroxide and chlorhexidine and immediately after this disinfection. Arm 2 - swab in oropharynx and saliva before application of solutions (T0), 30 min (T1) and 2 hours after application of solutions (T2). The quantification of SARS-CoV-2 will be done through the polymerase chain reaction with reverse-quantitative transcription (RT-qPCR). If some of these solutions are effective in reducing viral load in the oral cavity, this result may contribute to reduce the contamination of the environment caused by aerosols that require dental procedures, contributing to the improvement of biosafety protocols against SARS-CoV-2.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports